On November 10, WUXI BIO recorded an Intraday Rise of 3.13% in Regular Trading, trading at HK$50.4 with turnover of HK$110 million.
The move appears linked to continued market focus on the company’s recently announced long-term collaboration with Fresenius, together with supportive broker commentary pointing to potential guidance upside.
Background information shows the Fresenius agreement grants exclusive development options for up to 37 identified biosimilar candidates over 10 years, described as the largest development deal announced so far in the biosimilar industry. The referenced originator drugs correspond to combined annual list-price sales of more than EUR370 billion. More recently, Citi placed WUXI BIO on a 90-day positive catalyst watchlist, saying the company could raise overall guidance in the fourth quarter and may also lift its long-term CMO revenue target, while UBS maintained a Buy rating and a HK$62 target price.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments